
Matthew Roden, Aktis Oncology CEO (MPM Capital)
Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM's platform take
Brian Goodman, Patrick Baeuerle and Todd Foley weren’t exactly looking to start a radiopharmaceuticals company.
Rather, the team at MPM Capital — which had been known for its willingness to seed and incubate new ideas for battling cancer — was searching for technologies that could confer “CAR-T like efficacy” in solid tumors. They went through antibody-drug conjugates, cell therapies and T cell engagers but very quickly got hooked on something else: alpha emitting particles.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters